Pharmacological macrophage inhibition decreases metastasis formation in a genetic model of pancreatic cancer

Gut

Volumn 66, Issue 7, 2017, Pages 1278-1285

  Griesmann, Heidi ^a,b   Drexel, Christof ^b   Milosevic, Nada ^b   Sipos, Bence ^c   Rosendahl, Jonas ^a   Gress, Thomas M ^b   Michl, Patrick ^a,b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

ANGIOGENESIS; MACROPHAGES; PANCREATIC CANCER

Indexed keywords

CD11B ANTIGEN; CLODRONIC ACID; LIPOSOME; PHOSPHATE BUFFERED SALINE; VASCULOTROPIN; ANTINEOPLASTIC AGENT; INTERLEUKIN 2 RECEPTOR ALPHA; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INCIDENCE; CANCER INHIBITION; CARCINOGENESIS; CD4+ CD25+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENETIC MODEL; IMMUNOCOMPETENT CELL; LIVER; LUNG; MACROPHAGE MIGRATION INHIBITION; METASTASIS INHIBITION; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PRIMARY TUMOR; PRIORITY JOURNAL; SPLEEN; TREATMENT DURATION; ANIMAL; BIOLOGICAL MODEL; BLOOD; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; DRUG EFFECTS; EXPERIMENTAL NEOPLASM; IMMUNOLOGY; LIVER TUMOR; LUNG TUMOR; MACROPHAGE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PANCREAS TUMOR; PATHOLOGY; SECONDARY; T LYMPHOCYTE; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD11B; ANTINEOPLASTIC AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CLODRONIC ACID; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LIPOSOMES; LIVER NEOPLASMS; LUNG NEOPLASMS; MACROPHAGES; MICE; MODELS, GENETIC; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; T-LYMPHOCYTES; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84962868924     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-310049     Document Type: Article

References (38)

1. Clark CE, Beatty GL, Vonderheide RH. Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. Cancer Lett 2009;279:1-7.
2. Kurahara H, Takao S, Maemura K, et al. M2-polarized tumour-associated macrophage infiltration of regional lymph nodes is associated with nodal lymphangiogenesis and occult nodal involvement in pN0 pancreatic cancer. Pancreas 2013;42:155-9.
3. Neesse A, Michl P, Frese KK, et al. Stromal biology and therapy in pancreatic cancer. Gut 2011;60:861-8.
4. Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumour stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011;331:1612-16.
5. Bayne LJ, Beatty GL, Jhala N, et al. Tumour-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 2012;21:822-35.
6. De Palma M, Lewis CE. Macrophage regulation of tumour responses to anticancer therapies. Cancer Cell 2013;23:277-86.
7. Sica A, Larghi P, Mancino A, et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008;18:349-55.
8. Kurahara H, Shinchi H, Mataki Y, et al. Significance of M2-polarized tumour-associated macrophage in pancreatic cancer. J Surg Res 2011;167: e211-19.
9. van Rooijen N. Liposomes as an in vivo tool to study and manipulate macrophage function. Res Immunol 1992;143:177-8.
10. van Rooijen N, van Kesteren-Hendrikx E. Clodronate liposomes: perspectives in research and therapeutics. J Liposome Res 2002;12:81-94.
11. Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005;7:469-83.
12. Duffield JS, Forbes SJ, Constandinou CM, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005;115:56-65.
13. Lindau D, Gielen P, Kroesen M, et al. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 2013;138:105-15.
14. Yuan ZY, Luo RZ, Peng RJ, et al. High infiltration of tumour-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis. Onco Targets Ther 2014;7:1475-80.
15. Chang WJ, Du Y, Zhao X, et al. Inflammation-related factors predicting prognosis of gastric cancer. World J Gastroenterol 2014;20:4586-96.
16. Hiroshima Y, Maawy A, Hassanein MK, et al. The tumour-educated-macrophage increase of malignancy of human pancreatic cancer is prevented by zoledronic Acid. PLoS One 2014;9:e103382.
17. Lee CH, Espinosa I, Vrijaldenhoven S, et al. Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res 2008;14:1423-30.
18. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009;9:239-52.
19. Noy R, Pollard JW. Tumour-associated macrophages: from mechanisms to therapy. Immunity 2014;41:49-61.
20. Mazzieri R, Pucci F, Moi D, et al. Targeting the ANG2/TIE2 axis inhibits tumour growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011;19:512-26.
21. Kujawski M, Kortylewski M, Lee H, et al. Stat3 mediates myeloid cell-dependent tumour angiogenesis in mice. J Clin Invest 2008;118:3367-77.
22. Sun B, Karin M. The therapeutic value of targeting inflammation in gastrointestinal cancers. Trends Pharmacol Sci 2014;35:349-57.
23. Shojaei F, Wu X, Malik AK, et al. Tumour refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 2007;25:911-20.
24. Qian B, Deng Y, Im JH, et al. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One 2009;4: e6562.
25. Mitchem JB, Brennan DJ, Knolhoff BL, et al. Targeting tumour-infiltrating macrophages decreases tumour-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res 2013;73:1128-41.
26. Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer 2013;13:871-82.
27. DeNardo DG, Brennan DJ, Rexhepaj E, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011;1:54-67.
28. Facciabene A, Peng X, Hagemann IS, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011;475:226-30.
29. Partecke LI, Günther C, Hagemann S, et al. Induction of M2-macrophages by tumour cells and tumour growth promotion by M2-macrophages: a quid pro quo in pancreatic cancer. Pancreatology 2013;13:508-16.
30. Zeisberger SM, Odermatt B, Marty C, et al. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer 2006;95:272-81.
31. Reusser NM, Dalton HJ, Pradeep S, et al. Clodronate inhibits tumour angiogenesis in mouse models of ovarian cancer. Cancer Biol Ther 2014;15:1061-7.
32. Zhang W, Zhu XD, Sun HC, et al. Depletion of tumour-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res 2010;16:3420-30.
33. Rietkötter E, Menck K, Bleckmann A, et al. Zoledronic acid inhibits macrophage/microglia-assisted breast cancer cell invasion. Oncotarget 2013;4:1449-60.
34. Rogers TL, Wind N, Hughes R, et al. Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models. Cell Oncol (Dordr) 2013;36:505-14.
35. Melani C, Sangaletti S, Barazzetta FM, et al. Amino-bisphosphonate-mediated MMP-9 inhibition breaks the tumour-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumour stroma. Cancer Res 2007;67:11438-46.
36. Slingerland M, Guchelaar HJ, Gelderblom H. Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov Today 2012;17:160-6.
37. Paulus P, Stanley ER, Schäfer R, et al. Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. Cancer Res 2006;66:4349-56.
38. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 1994;174:83-93.